Provider Concentration: The Number One Thing That Lowers Your Med Spa's Price
If one injector produces most of your revenue, especially you, buyers price it as a risk. On a $500K business, provider concentration can be a $750,000 problem. Here is how buyers measure it and how to reduce it before you sell.
The risk hiding inside your best year
You can have rising revenue, loyal patients, and a strong brand, and still get a low offer for one reason: too much of your revenue depends on one person. Usually that person is you.
Buyers call it provider concentration, or key-person risk, and it's the single most common thing that lowers a med spa's price. A spa where one injector produces 70% of clinical revenue isn't a business a buyer can safely run. It's a bet on whether that injector stays. Buyers price bets conservatively, with a lower multiple, a bigger earnout, or a pass. Here's how the risk works and how to reduce it in the year before you sell.
Why concentration scares buyers
When a buyer acquires your spa, they're buying future cash flow. If most of that cash flow comes from one provider, the buyer's real question is: what happens to revenue if this person leaves six months after close?
For the owner-operator, the risk is double. Not only do you produce a large share of revenue, but you're also the person selling and planning to leave or step back. The buyer has to replace your production and absorb the patient attrition that often follows a beloved provider's exit. That's why an owner who's also the top biller gets discounted twice: once for the concentration, once for being the one who's leaving.
The math is stark. On a spa earning $500,000 in adjusted EBITDA, moving from a 4x multiple (high concentration) to a 5.5x multiple (diversified) is the difference between $2.0M and $2.75M. Provider concentration is a $750,000 problem.
How buyers measure it
You don't get to describe your concentration. The buyer measures it from your data. They'll look at:
- Percentage of clinical revenue produced by each provider
- Percentage produced by the owner specifically
- How patients are distributed across providers
- Whether patients rebook with the practice or with a named person
- Tenure and contract status of each provider
The number that matters most is the share held by your single largest provider. As a rough guide to how buyers read it:
| Top provider's share of revenue | How buyers read it |
|---|---|
| Over 60% | High risk. Expect a discount or a heavy earnout. |
| 40% to 60% | Moderate risk. Manageable with retention terms. |
| 25% to 40% | Healthy. A normal, financeable business. |
| Under 25% | Strong. Reads as a true platform asset. |
Fix 1: Redistribute patients deliberately
The most direct fix is to spread patient load across more providers, and it takes time, which is why you start a year out. When a loyal patient books with you, route the routine follow-up visits to another qualified provider. Introduce patients to the team as "your care team," not "me." Position it as an upgrade in access, not a downgrade from you.
Done over months, this shifts both revenue and, more importantly, loyalty. The goal is patients who are loyal to the practice and comfortable with several providers, so no single exit takes the relationship with it.
Fix 2: Add or develop a second high-producer
If your team is thin, hire. A second strong injector who's been productive for six to twelve months before you sell changes your risk profile materially. Buyers can see the revenue isn't yours alone.
Hiring an injector takes time to recruit, onboard, and ramp, so this is a months-12-to-6 task, not a months-3-to-1 task. If you can't hire, develop: invest in the training and patient exposure of the providers you already have so their production climbs before you go to market.
Fix 3: Lock your team in place
Concentration risk isn't only about who produces revenue. It's about whether they stay. Clean, current employment agreements with reasonable non-solicit terms tell a buyer your providers won't walk out and take patients on day one.
Make sure classification is correct (employee versus contractor), that non-solicit and confidentiality terms are enforceable in your state, and that your compensation structure gives providers a reason to stay through a transition. Retention bonuses tied to staying twelve or twenty-four months post-close are common and reassuring to buyers.
Fix 4: Build brand loyalty, not personal loyalty
The deepest fix is cultural. Patients who chose your spa because of your marketing, your space, your consistent results, and your membership program are loyal to the business. Patients who chose it because of you specifically leave when you do.
Shift the loyalty by investing in the brand: consistent protocols so every provider delivers the same result, a membership program that ties patients to the practice, a patient experience that doesn't depend on one personality. A membership program does double duty here, since recurring revenue also lifts your multiple on its own.
What "fixed" looks like in diligence
A buyer reviewing a de-risked spa sees revenue spread across three or four productive providers, no single one above 40%, patients who rebook with the practice, current agreements with retention terms, and a membership base that proves loyalty to the brand. That business finances cleanly and closes at its LOI price.
Compare that to a spa where the owner produces 70% of revenue, has no employment agreements, and whose patients book only with them. Same revenue, very different offer, if an offer comes at all.
Start before you need to
Provider concentration is slow to build and slow to fix, which is exactly why it separates prepared sellers from rushed ones. You can't diversify a patient base in six weeks. You can over twelve months.
The first step is knowing where you stand. A valuation shows you your current concentration and how much it's costing your multiple. Get a confidential valuation, then spend the year moving your top provider's share down and your multiple up. It's some of the highest-return work you can do before a sale, and it's covered in sequence in the 12-month pre-sale plan.